|
Orthologous residues
|
|
USP10 (human): T42‑p, USP10 (mouse): I41‑p, USP10 (rat): I41‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site
|
|
Disease tissue studied:
colorectal cancer, colorectal carcinoma, kidney cancer
|
|
Relevant cell lines - cell types - tissues:
HCT116 (intestinal), kidney
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ATM (human)
|
modification site within consensus motif, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
ionizing radiation
|
|
|
|
increase
|
|
|
KU-55933
|
ionizing radiation
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, protein stabilization, ubiquitination
|
|
Effect of modification (process):
carcinogenesis, inhibited, cell growth, altered
|
|
Comments:
regulates p53 homeostasis
|